A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

October 3, 2025

Conditions
Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell CarcinomaLiver Cell Carcinoma, Adult
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Relatlimab

Specified dose on specified days

Trial Locations (65)

0

Local Institution - 0077, Hksar

Local Institution - 0079, Shatin

100

Local Institution - 0031, Taipei

333

Local Institution - 0032, Taoyuan District

704

Local Institution - 0034, Tainan City

1023

Local Institution - 0003, Auckland

1181

Local Institution - 0010, Ciudad de Buenos Aires

4000

Local Institution - 0063, San Miguel de Tucumán

11217

Local Institution - 0042, Taipei

13496

Local Institution - 0020, Seongnam-si

14004

Local Institution - 0073, Córdoba

20014

Local Institution - 0050, Donostia / San Sebastian

22030

Local Institution - 0090, Edirne

28009

Local Institution - 0051, Madrid

28041

Local Institution - 0049, Madrid

31008

Local Institution - 0058, Pamplona

33600

Local Institution - 0067, Pessac

38043

Local Institution - 0105, Grenoble

40447

Local Institution - 0041, Taichung

41380

Local Institution - 0091, Kadiköy/Istanbul

50005

Local Institution - 0047, Hradec Králové

54511

Local Institution - 0069, Vandœuvre-lès-Nancy

65653

Local Institution - 0048, Brno

68020

Local Institution - 0106, Oaxaca City

69004

Local Institution - 0074, Lyon

78250

Local Institution - 0101, San Luis Potosí City

92110

Local Institution - 0068, Clichy

150081

Local Institution - 0113, Harbin

168583

Local Institution - 0001, Singapore

200032

Local Institution - 0107, Shanghai

200542

Local Institution - 0038, Craiova

308433

Local Institution - 0004, Singapore

310016

Local Institution - 0117, Hangzhou

400015

Local Institution - 0036, Cluj-Napoca

410013

Local Institution - 0114, Changsha

710061

Local Institution - 0118, Xi'an

710126

Local Institution - 0108, Xi'an

720214

Local Institution - 0070, Suceava

4800827

Local Institution - 0024, Temuco

8420383

Local Institution - 0018, Santiago

14784400

Local Institution - 0016, Barretos

C1096AAS

Local Institution - 0019, Buenos Aires

S2002KDS

Local Institution - 0017, Rosario

30130-090

Local Institution - 0025, Belo Horizonte

91350-200

Local Institution - 0060, Porto Alegre

14051-140

Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology, Ribeirão Preto

01246-000

Local Institution - 0015, São Paulo

000000

Local Institution - 0029, Santiago

140 59

Local Institution - 0046, Prague

790-0024

Local Institution - 0072, Matsuyama

232-0024

Local Institution - 0054, Yokohama

241-8515

Local Institution - 0076, Yokohama

589-8511

Local Institution - 0045, Ōsaka-sayama

920-8641

Local Institution - 0075, Ishikawa

602-8566

Local Institution - 0071, Kyoto

06700

Local Institution - 0100, Cuauhtémoc

31-501

Local Institution - 0013, Krakow

41-900

Local Institution - 0012, Bytom

41-400

Local Institution - 0009, Mysowice

02-034

Local Institution - 0039, Warsaw

022328

Local Institution - 0037, Bucharest

05505

Local Institution - 0011, Seoul

06351

Local Institution - 0043, Seoul

08036

Local Institution - 0066, Barcelona

06230

Local Institution - 0089, Ankara

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04567615 - A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | Biotech Hunter | Biotech Hunter